{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:35Z","timestamp":1792202375234,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12936-017-1914-9","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T08:14:27Z","timestamp":1499069667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women"],"prefix":"10.1186","volume":"16","author":[{"given":"Ritah F.","family":"Mutagonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Appolinary A. R.","family":"Kamuhabwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omary M. S.","family":"Minzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriel N.","family":"Massawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manijeh V.","family":"Homann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"F\u00e4rnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"key":"1914_CR1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00228-006-0199-7","volume":"62","author":"R McGready","year":"2006","unstructured":"McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62:1021\u201331.","journal-title":"Eur J Clin Pharmacol"},{"key":"1914_CR2","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1371\/journal.pmed.0050253","volume":"5","author":"R McGready","year":"2008","unstructured":"McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5:e253.","journal-title":"PLoS Med"},{"key":"1914_CR3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/138920009788897993","volume":"10","author":"P Pavek","year":"2009","unstructured":"Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab. 2009;10:520\u20139.","journal-title":"Curr Drug Metab"},{"key":"1914_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1473-3099(07)70025-7","volume":"7","author":"SA Ward","year":"2007","unstructured":"Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7:136\u201344.","journal-title":"Lancet Infect Dis"},{"key":"1914_CR5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","volume":"44","author":"GD Anderson","year":"2005","unstructured":"Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989\u20131008.","journal-title":"Clin Pharmacokinet"},{"key":"1914_CR6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","volume":"41","author":"N Isoherranen","year":"2013","unstructured":"Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41:256\u201362.","journal-title":"Drug Metab Dispos"},{"key":"1914_CR7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/17425251003677755","volume":"6","author":"H Jeong","year":"2010","unstructured":"Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6:689\u201399.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1914_CR8","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1128\/AAC.01700-12","volume":"57","author":"EM Staehli Hodel","year":"2013","unstructured":"Staehli Hodel EM, Csajka C, Ariey F, Guidi M, Kabanywanyi AM, Duong S, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother. 2013;57:950\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1914_CR9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/FTD.0b013e3181da79d6","volume":"32","author":"JK Mukonzo","year":"2010","unstructured":"Mukonzo JK, Waako P, Ogwal-Okeng J, Gustafsson LL, Aklillu E. Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans. Ther Drug Monit. 2010;32:346\u201352.","journal-title":"Ther Drug Monit"},{"key":"1914_CR10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1517\/17425255.2011.608660","volume":"7","author":"R Piedade","year":"2011","unstructured":"Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol. 2011;7:1185\u2013200.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1914_CR11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.fpc.0000230411.89973.1b","volume":"16","author":"RA Mirghani","year":"2006","unstructured":"Mirghani RA, Sayi J, Aklillu E, Allqvist A, Jande M, Wennerholm A, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genom. 2006;16:637\u201345.","journal-title":"Pharmacogenet Genom"},{"key":"1914_CR12","doi-asserted-by":"crossref","first-page":"e40180","DOI":"10.1371\/journal.pone.0040180","volume":"7","author":"S Mugusi","year":"2012","unstructured":"Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, et al. Liver enzyme abnormalities and associated risk factors in HIV patients on Efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS ONE. 2012;7:e40180.","journal-title":"PLoS ONE"},{"key":"1914_CR13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/tpj.2010.16","volume":"11","author":"E Gebeyehu","year":"2011","unstructured":"Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E. Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenom J. 2011;11:130\u20137.","journal-title":"Pharmacogenom J"},{"key":"1914_CR14","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1089\/omi.2013.0140","volume":"18","author":"E Aklillu","year":"2014","unstructured":"Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS. 2014;18:446\u201353.","journal-title":"OMICS"},{"key":"1914_CR15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/tpj.2012.46","volume":"13","author":"A Habtewold","year":"2013","unstructured":"Habtewold A, Amogne W, Makonnen E, Yimer G, Nylen H, Riedel KD, et al. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenom J. 2013;13:484\u20139.","journal-title":"Pharmacogenom J"},{"key":"1914_CR16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/omi.2015.0022","volume":"19","author":"FH Hatta","year":"2015","unstructured":"Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, et al. Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: role of ethnicity, genotype, smoking, age, and sex. OMICS. 2015;19:346\u201353.","journal-title":"OMICS"},{"key":"1914_CR17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1128\/AAC.05756-11","volume":"56","author":"J Tarning","year":"2012","unstructured":"Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56:1997\u20132007.","journal-title":"Antimicrob Agents Chemother"},{"key":"1914_CR18","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1038\/psp.2013.59","volume":"2","author":"F Kloprogge","year":"2013","unstructured":"Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, et al. Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. CPT Pharmacometr Syst Pharmacol. 2013;2:e83.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1914_CR19","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1128\/AAC.02595-14","volume":"58","author":"D Mosha","year":"2014","unstructured":"Mosha D, Guidi M, Mwingira F, Abdulla S, Mercier T, Decosterd LA, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58:4583\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"1914_CR20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12936-016-1327-1","volume":"15","author":"RF Mutagonda","year":"2016","unstructured":"Mutagonda RF, Kamuhabwa AA, Minzi OM, Massawe SN, Maganda BA, Aklillu E. Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women. Malar J. 2016;15:278.","journal-title":"Malar J"},{"key":"1914_CR21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12936-015-0695-2","volume":"14","author":"BA Maganda","year":"2015","unstructured":"Maganda BA, Ngaimisi E, Kamuhabwa AA, Aklillu E, Minzi OM. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Malar J. 2015;14:179.","journal-title":"Malar J"},{"key":"1914_CR22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/tpj.2015.37","volume":"16","author":"BA Maganda","year":"2016","unstructured":"Maganda BA, Minzi OM, Ngaimisi E, Kamuhabwa AA, Aklillu E. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. Pharmacogenom J. 2016;16:88\u201395.","journal-title":"Pharmacogenom J"},{"key":"1914_CR23","doi-asserted-by":"crossref","first-page":"e67946","DOI":"10.1371\/journal.pone.0067946","volume":"8","author":"E Ngaimisi","year":"2013","unstructured":"Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS ONE. 2013;8:e67946.","journal-title":"PLoS ONE"},{"key":"1914_CR24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/clpt.2011.129","volume":"90","author":"E Ngaimisi","year":"2011","unstructured":"Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel K, Suda A, et al. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther. 2011;90:406\u201313.","journal-title":"Clin Pharmacol Ther"},{"key":"1914_CR25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1473-3099(10)70202-4","volume":"10","author":"P Piola","year":"2010","unstructured":"Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2010;10:762\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"1914_CR26","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","volume":"8","author":"A Djimde","year":"2009","unstructured":"Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J. 2009;8(Suppl 1):S4.","journal-title":"Malar J"},{"key":"1914_CR27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-200847020-00002","volume":"47","author":"PI German","year":"2008","unstructured":"German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet. 2008;47:91\u2013102.","journal-title":"Clin Pharmacokinet"},{"key":"1914_CR28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1128\/JCM.01858-08","volume":"47","author":"SE Shokoples","year":"2009","unstructured":"Shokoples SE, Ndao M, Kowalewska-Grochowska K, Yanow SK. Multiplexed real-time PCR assay for discrimination of Plasmodium species with improved sensitivity for mixed infections. J Clin Microbiol. 2009;47:975\u201380.","journal-title":"J Clin Microbiol"},{"key":"1914_CR29","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization. 2008. \n                        http:\/\/whqlibdoc.who.int\/publications\/2008\/9789241596305_eng.pdf?ua=1\n                        \n                    . Accessed 30 Dec 2016."},{"key":"1914_CR30","first-page":"131","volume":"3","author":"OM Minzi","year":"2012","unstructured":"Minzi OM, Ngaimisi E, Shewiyo DH, Sasi P, Ignace AI. Interlaboratory development and cross validation of a chromatographic method for determination of lumefantrine in human plasma-a proficient capacity assessment of bioanalytical laboratories in East Africa. J Anal Bioanal Tech. 2012;3:131.","journal-title":"J Anal Bioanal Tech"},{"key":"1914_CR31","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization. 2009. \n                        http:\/\/whqlibdoc.who.int\/publications\/2009\/9789241597531_eng.pdf\n                        \n                    . Accessed 1 Jan 2017."},{"key":"1914_CR32","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1128\/AAC.00683-13","volume":"57","author":"J Tarning","year":"2013","unstructured":"Tarning J, Kloprogge F, Dhorda M, Jullien V, Nosten F, White NJ, et al. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Antimicrob Agents Chemother. 2013;57:5096\u2013103.","journal-title":"Antimicrob Agents Chemother"},{"key":"1914_CR33","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dku286","volume":"69","author":"E Ngaimisi","year":"2014","unstructured":"Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, et al. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4beta-hydroxycholesterol during efavirenz treatment and efavirenz\/rifampicin co-treatment. J Antimicrob Chemother. 2014;69:3311\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1914_CR34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/FPC.0b013e3282f50ee9","volume":"18","author":"U Diczfalusy","year":"2008","unstructured":"Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, et al. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genom. 2008;18:201\u20138.","journal-title":"Pharmacogenet Genom"},{"key":"1914_CR35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","volume":"30","author":"JA Williams","year":"2002","unstructured":"Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30:883\u201391.","journal-title":"Drug Metab Dispos"},{"key":"1914_CR36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/beog.2001.0231","volume":"15","author":"M Dawes","year":"2001","unstructured":"Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819\u201326.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1914_CR37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/em.10199","volume":"42","author":"B Amirimani","year":"2003","unstructured":"Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen. 2003;42:299\u2013305.","journal-title":"Environ Mol Mutagen"},{"key":"1914_CR38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2005.09.020","volume":"338","author":"C Rodriguez-Antona","year":"2005","unstructured":"Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun. 2005;338:299\u2013305.","journal-title":"Biochem Biophys Res Commun"},{"key":"1914_CR39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4196\/kjpp.2013.17.6.479","volume":"17","author":"JS Lee","year":"2013","unstructured":"Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH, et al. Screening of genetic polymorphisms of CYP3A4 and CYP3A5 genes. Korean J Physiol Pharmacol. 2013;17:479\u201384.","journal-title":"Korean J Physiol Pharmacol"},{"key":"1914_CR40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.9210","volume":"23","author":"H Fukushima-Uesaka","year":"2004","unstructured":"Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat. 2004;23:100.","journal-title":"Hum Mutat"},{"key":"1914_CR41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","volume":"54","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271\u201394.","journal-title":"Adv Drug Deliv Rev"},{"key":"1914_CR42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/94.8.630","volume":"94","author":"L Wojnowski","year":"2002","unstructured":"Wojnowski L, Hustert E, Klein K, Goldammer M, Haberl M, Kirchheiner J, et al. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 2002;94:630\u20131.","journal-title":"J Natl Cancer Inst"},{"key":"1914_CR43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00008571-200310000-00004","volume":"13","author":"H Dally","year":"2003","unstructured":"Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, et al. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13:607\u201318.","journal-title":"Pharmacogenetics"},{"key":"1914_CR44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1089\/omi.2016.0119","volume":"20","author":"E Aklillu","year":"2016","unstructured":"Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, et al. SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: relevance for African and worldwide precision medicine. OMICS. 2016;20:538\u201345.","journal-title":"OMICS"},{"key":"1914_CR45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.genom.9.081307.164258","volume":"9","author":"MC Campbell","year":"2008","unstructured":"Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genom Hum Genet. 2008;9:403\u201333.","journal-title":"Annu Rev Genom Hum Genet"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-1914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T08:14:41Z","timestamp":1499069681000},"score":1,"resource":{"primary":{"URL":"http:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-017-1914-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1186\/s12936-017-1914-9","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]},"article-number":"267"}}